Boston Scientific Corporation financials
Key figures from Boston Scientific Corporation's filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | $5.4B | $5.1B | +7.5% |
| Net income | $907M | $797M | +13.8% |
| Free cash flow | $1.3B | $1.1B | +13.3% |
| Gross margin | 70.7% | 67.7% | +3.1 pts |
| Operating margin | 21.6% | 16.2% | +5.5 pts |
| Net margin | 16.7% | 15.7% | +0.9 pts |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Dec 2025 | $20.1B | $2.9B | 14.4% | $3.7B | $1.94 |
| FY Dec 2024 | $16.7B | — | — | $2.6B | $1.25 |
| FY Dec 2023 | $14.2B | — | — | $1.8B | $1.07 |
| FY Dec 2022 | $12.7B | — | — | $938M | $0.45 |
| FY Dec 2021 | $11.9B | — | — | $1.3B | $0.69 |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.